Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Analysis 2025–2029: Growth Forecast and Competitive Insights
Uncover key drivers, emerging technologies, and competitive movements shaping the benign prostatic hyperplasia (bph) treatment devices and equipment market from 2025–2034 with trusted insights from The Business Research Company
How Much Will The Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Be Worth By 2029, And What CAGR Will It Achieve?
The market for benign prostatic hyperplasia (bph) treatment devices and equipment has experienced robust growth in recent years. This market is projected to expand from $1.27 billion in 2024 to $1.34 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.9%. Historically, this expansion has been driven by factors such as an aging population, increased awareness and diagnosis, improved healthcare access, and the rise of personalized treatment approaches.
The benign prostatic hyperplasia (bph) treatment devices and equipment market size is projected to experience robust growth over the next few years. It is forecast to expand to $1.74 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.6%. The expansion during the forecast period is primarily driven by factors such as minimally invasive techniques, the growth of emerging markets, supportive regulatory frameworks, and the emphasis on value-based healthcare. Prominent trends expected in this period include the increasing adoption of non-surgical and office-based procedures, advancements in laser and radiofrequency technologies, the widespread use of telemedicine and remote consultation, and enhanced patient education and engagement.
Access A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2431&type=smp
Which Factors Are Driving The Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Forward?
The rise in prostate cancer occurrences is expected to boost the benign prostatic hyperplasia market going forward. Prostate cancer is a malignancy that develops within the prostate gland, which is a small, walnut-sized gland situated just below the bladder in men. An uptick in prostate cancer cases often leads to more older men seeking medical attention for prostate-related issues, subsequently resulting in the identification and management of benign prostatic hyperplasia. For instance, in February 2023, the American Society of Clinical Oncology (ASCO), a US-based professional organization that publishes patient information on the cancer.net website, reported an estimated 288,300 men in the United States were living with prostate cancer in 2023. Additionally, in 2022, 268,490 new cases and 34,500 deaths were attributed to prostate cancer. Consequently, the increasing number of prostate cancer cases is propelling the growth of the benign prostatic hyperplasia market.
Which Segments Form The Key Structure Of The Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?
The benign prostatic hyperplasia (bph) treatment devices and equipmentmarket covered in this report is segmented –
1) By Product: Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants
2) By Procedure Type: Transurethral Needle Ablation (TUNA), Transurethral Resection Of Prostate (TURP), Transurethral Incision Of Prostate (TUIP), Transurethral Microwave Thermotherapy (TUMT), Laser Surgery, Other Procedure Types
3) By End-User: Hospitals, Ambulatory Surgical Centres (ASC), Clinics, Home
Subsegments:
1) By Resectoscopes: Bipolar Resectoscopes, Monopolar Resectoscopes, High-Performance Resectoscopes
2) By Radiofrequency Ablation Device: Single-Needle Radiofrequency Ablation, Multi-Needle Radiofrequency Ablation
3) By Urology Lasers: Holmium Lasers, Diode Lasers, Green Light Lasers
4) By Prostatic Stents: Temporary Prostatic Stents, Permanent Prostatic Stents
5) By Implants: Prostatic Urethral Lift (PUL) Implants, Balloon-Expandable Stents, Permanent Implants for BPH Treatment
How Are Global Trends Impacting The Development Of The Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?
Leading firms within the benign prostatic hyperplasia market are prioritizing the creation of novel products, including the UroLift 2 System and the UroLift ATC advanced tissue control system, with the aim of delivering dependable solutions to the market. Both the UroLift 2 System and the UroLift ATC advanced tissue control system have been introduced to address lower urinary tract symptoms stemming from benign prostatic hyperplasia (BPH). An example of this is seen in May 2022, when Teleflex Incorporated, a US-based medical device company, rolled out the UroLift 2 System and UroLift ATC. The UroLift 2 System functions as a delivery mechanism intended for reaching the prostatic urethra and implanting permanent UroLift devices through prostate lobes, while the UroLift ATC advanced tissue control system offers a less invasive method for managing symptoms associated with an enlarged prostate. This represents a progressive method for treating benign prostatic hyperplasia (BPH) by lifting and securing the enlarged prostate tissue, thereby preventing it from obstructing the urethra.
Which Firms Are Making The Biggest Impact In The Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?
Major companies operating in the benign prostatic hyperplasia (BPH) treatment devices and equipment market include Karl Storz, Lumenis Ltd., Olympus Corporation, Urologix LLC, Boston scientific Inc., Endo International plc, NeoTract Inc., OmniGuide Inc., Medifocus Inc., ProArc Medical Ltd., Teleflex Incorporated, Medtronic plc, Urotech Devices, Prostalund Operations AB, Baxter International, NxThera Inc., Richard Wolf GmbH, Coloplast A/S, Siemens Healthineers, Quest Pharmatech, Protox Therapeutics, IntelGenx Technologies Corp, Astellas Pharma Inc., Ipsen S.A., Biolitec AG, BVM Medical, Convergent Laser Technologies, Cook Medical, GreenLight Technologies, Merit Medical Systems, Pnn Medical A/S, PROCEPT BioRobotics, Prosenex, ProSolv CardioVascular Inc., Quanta System, Rocamed SAM, RZ Medizintechnik GmbH, SRS Medical Systems, UroShape LLC, Vertebron Inc.
Download The Full Report Here:
Which Region Is Expected To Lead The Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market In The Next Few Years?
North America was the largest region in the benign prostatic hyperplasia (BPH) treatment devices and equipment market in 2024. Western Europe was the second-largest region in the global benign prostatic hyperplasia (BPH) treatment devices and equipment market. The regions covered in the benign prostatic hyperplasia (BNH) treatment devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Get A Report Customized For You Here:
https://www.thebusinessresearchcompany.com/customise?id=2431&type=smp
Browse Through More Reports Similar to the Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market 2025, By The Business Research Company
Prostate Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report
Radiofrequency Identification Tags Global Market Report 2025
Tumor Ablation Therapy Devices Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
